UNM Rainforest Innovations

Circular Genomics has recently raised $1.5 million to further expand its research and development operations and grow the company’s team. This is part of a $3.2 million offering the company first reported at the end of 2021.

Circular Genomics utilizes circular RNA to determine effective treatment options for people struggling with depression and neurological disorders. This new approach can better predict a patient’s sensitivity to anti-depressants by using circular RNA to measure the genes and proteins associated with those pathways. With this information, doctors could make better informed decisions when determining effective medication options for patients.

Circular Genomics’ circular RNA biomarker technology was developed by University of New Mexico researchers Dr. Nikolaos Mellios, assistant professor at UNM’s Neurosciences Department, and Dr. Alexander Hafez, who worked with Dr. Mellios as a doctoral candidate in biomedical science before graduating in January 2021. The third collaborator is Dr. Madhukar Trivedi, Professor of Psychiatry, Chief of the Division of Mood Disorders, and Director of the Center for Depression Research and Clinical Care at UT Southwestern Medical Center. Circular Genomics holds an exclusive license for the technology from UNM Rainforest Innovations.

Learn more about Circular Genomics here: https://www.circulargenomics.com/

See Jacob Maranda’s March 17 article, “Albuquerque bioscience startup raises $1.5M for RNA technology,” on the New Mexico Inno website here: https://www.bizjournals.com/albuquerque/inno/stories/fundings/2023/03/17/albuquerque-bioscience-startup-raise.html?utm_source=st&utm_medium=en&utm_campaign=me&utm_content=AQ&ana=e_AQ_me&j=30893317&senddate=2023-03-20

Skip to content